ISSN: 2155-9899
Department of Family Medicine, McLaren Bay Region, 4817 W Professional Dr, Bay City, MI 48706, USA
Review Article
Hydroxychloroquine and Interferons for the Prophylaxis and Early Treatment of Covid-19-Current Clinical Advances
Author(s): Alexander Chuan Yang, Youcheng Liu, Yongzhao Shao, Charlotte Zhong Yang, Jinping Xu* and Bing Yang*
Coronavirus disease 2019 (Covid-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) calls for unprecedented measures to control the spread of the virus. SARS-CoV-2 enters into the cell by
direct fusion to the cell membrane or fusion to the membrane of endocytic vesicles. Hydroxychloroquine (HCQ)
inhibits enzymes in the endocytic vesicle and has been studied for its efficacy since the beginning of the pandemic.
Retrospective analysis of healthcare workers (HCWs) and observational studies suggest protective effect of taking
HCQ prophylactically. However, studies on autoimmune patients taking HCQ provide conflicting results. In a
postexposure prophylaxis randomized controlled trial (RCT), Boulware et al. found a non-significant difference in
incidence between HCQ and placebo group (11.8% vs. 14.3%, p=0.35). However, our re-analysis of.. View More»
DOI:
10.35248/2155-9899.20.11.596